Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06959888 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

A Phase 1 study of Healthy Volunteer Study, sponsored by Aligos Therapeutics.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT06959888 is a Phase 1 study of Healthy Volunteer Study that has completed, run by Aligos Therapeutics. The registered enrollment target is 8 participants, below the 36-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06959888, a Phase 1 study of Healthy Volunteer Study, has completed, sponsored by Aligos Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1 single dose, open-label, randomized, two-period, two-sequence, crossover study of ALG-055009 conducted in 1 cohort of healthy volunteers. The primary purpose of this study is to compare the single-dose pharmacokinetics of the 0.7 mg dose level of 2 types of soft gelatin capsule formulations of ALG-055009, Formulation 1 and Formulation 2, in approximately 8 healthy volunteers.

Conditions Studied

Interventions

  • DRUG ALG-055009

Study Locations (1)

Texas

  • PPD Austin CRU - Austin

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2025-03-25
Est. Completion 2025-05-16
Phase Phase 1

Sponsor

Aligos Therapeutics

9 total trials

What the Registry Record Tells You About NCT06959888

The ClinicalTrials.gov registry entry for NCT06959888 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (78% lower). The listed sponsor is Aligos Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteer Study appearing as the primary indexed condition, and to 1 intervention - of which ALG-055009 is the first listed.

NCT06959888 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06959888 about?

NCT06959888 is a clinical study titled "A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations". This is a phase 1 single dose, open-label, randomized, two-period, two-sequence, crossover study of ALG-055009 conducted in 1 cohort of healthy volunteers. The primary purpose of this study is to compare the single-dose pharmacokinetics of the 0.7 mg dose level of 2 types of soft gelatin capsule for...

What is the current status of trial NCT06959888?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-03-25. Estimated completion is 2025-05-16.

What conditions does trial NCT06959888 study?

This clinical trial studies the following conditions: Healthy Volunteer Study.

What interventions are being tested in trial NCT06959888?

The interventions under investigation include: ALG-055009 (DRUG).

Who is sponsoring clinical trial NCT06959888?

This trial is sponsored by Aligos Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06959888 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer Study

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.